Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric Participants With KCNT1-Related Epilepsy

Next Previous
Trial Profile

A Phase 1b/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 Administered to Pediatric Participants With KCNT1-Related Epilepsy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABS 1230 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms KYRON
  • Sponsors Actio Biosciences

Most Recent Events

  • 08 May 2026 Status changed from planning to recruiting.
  • 13 Nov 2025 New trial record
  • 23 Sep 2025 According to Actio Biosciences media release, a proof-of-concept Phase 1b/2a study of ABS-1230 in KCNT1-related epilepsy patients in the U.S. in early 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top